Back to A
Agilent (A): Valuation and Earnings Outlook
$ANEUTRALHealthcare

Agilent (A): Valuation and Earnings Outlook

Agilent closed Friday, November 13, at $173.96, near its 52-week high, after a reported quarterly EPS beat. Analyst views are generally favorable, but the supplied mean target is close to the market price and valuation remains an important risk ahead of the November 23 earnings report.

November 14, 202610 min read
Current Price
$173.96
+0.55%
Analyst Rating
Strong Buy
Price Target
$174.29
0.2% upside
P/E Ratio
34.18

Executive Summary

Investment Thesis: Agilent combines a broad life-sciences and analytical-instrument portfolio with recurring demand for consumables and services. Its latest reported quarter delivered an EPS beat, and analysts in the supplied survey are mostly positive. At $173.96, however, the supplied average price target is only slightly higher, while a 34.18 trailing P/E and a November 23 earnings report make valuation and execution important near-term considerations.

Current Price: $173.96 as of Friday, November 13 | Key Metric: 34.18 trailing P/E | Stance: NEUTRAL

US markets are closed on Saturday, November 14. The price and daily change in this report refer to Friday’s close, when $A rose $0.95, or 0.55%, from $173.01. The neutral stance reflects a balance between positive company and analyst signals and a valuation that appears to leave little implied gain using the supplied mean target.

Company Overview

Agilent Technologies, Inc. ($A) supplies analytical instruments, software, services, and laboratory solutions used in pharmaceutical and biotechnology research, diagnostics, chemicals, food testing, and other regulated industries. Its products help customers measure, analyze, and validate samples, making reliability and compliance important purchasing considerations.

Key Products & Competitive Position

  • Core Business: Laboratory measurement and analysis tools, complemented by service, maintenance, and consumables revenue.
  • Key Products: Chromatography, mass spectrometry, spectroscopy, and related software and laboratory services. Agilent also offers genomics and next-generation sequencing research products, including the recently announced SureSelect Cancer Research Pan Heme.
  • Competitive Moat: Established customer relationships, specialized technical expertise, installed instruments, and the costs and validation work involved when laboratories change methods or suppliers. These advantages can support repeat business, though they do not eliminate competition or cyclical spending.

Recent Developments

Agilent announced on November 10 that it was expanding its research portfolio with SureSelect Cancer Research Pan Heme, a hybrid-capture next-generation sequencing research solution. The product addresses cancer research applications, but the supplied announcement does not quantify expected sales or financial impact. On November 12, the company said management would participate in the 9th Annual Evercore Healthcare Conference, an opportunity to discuss its business and outlook rather than a disclosed earnings catalyst.

Financial Snapshot

Market Cap$49.05B
P/E Ratio34.18
52-Week Range$108.35 - $182.99
Dividend Yield0.59%
EPS (TTM)$5.11
ROE20.47%

Revenue & Earnings Trends

The available financial snapshot lists trailing EPS of $5.11, while a separate Yahoo Finance extract reports $5.07. The same extract lists revenue of approximately $7.37 billion, revenue growth of 8.1%, earnings growth of 8.5%, and a 19.53% profit margin. These figures point to recent growth, but the reporting periods and data vendors may differ, so they should not be treated as a single audited-period comparison.

The latest supplied earnings result, dated August 26, was EPS of $1.62 versus an estimate of $1.49, a $0.13 beat. That is encouraging, though one quarter alone does not establish a sustained trend. The next report is expected November 23, with consensus EPS estimated at $1.73.

Balance Sheet Highlights

Agilent’s current ratio of 2.05 indicates current assets exceed current liabilities by a little more than two times. The supplemental snapshot reports $1.76 billion of cash, $4.15 billion of debt, and $1.06 billion in free cash flow. Debt is meaningful relative to cash, but reported free cash flow and a 20.47% supplied ROE offer context for its capacity to fund operations and shareholder distributions. The supplemental source gives ROE as 20.97%, another small vendor difference.

Valuation Analysis

Current Valuation Metrics

Forward P/E25.9Industry comparison not supplied
PEG Ratio1.46Supplemental data snapshot
EV/EBITDA24.7Historical comparison not supplied
P/S Ratio6.65Peer comparison not supplied

Historical Comparison

A verified five-year average valuation and comparable-company multiples were not included in the supplied data, so a precise historical or peer premium cannot be established here. The trailing P/E of 34.18 and price-to-book ratio of 6.66 indicate that the market assigns a substantial value to Agilent’s earnings and equity. The supplemental forward P/E of 25.89 is lower than the trailing multiple, reflecting expected earnings growth in that data snapshot, not a guaranteed outcome.

Fair Value Estimate

The supplied analyst target set places the mean at $174.29, just 0.2% above Friday’s close, with a range of $150 to $195. A separate Yahoo Finance snapshot gives a higher mean of $182.05 and a $155 to $200 range, highlighting that target estimates vary by provider and analyst coverage. With no detailed cash-flow forecast, discount rate, or long-term growth assumptions supplied, a standalone DCF estimate would imply unsupported precision. On the available evidence, valuation looks sensitive to the pace of earnings growth and the November report.

Competitive Landscape

Market Position

Market Share: Not provided in the available data | Ranking: Not independently established here; Agilent is a major supplier in analytical laboratory technologies

Key Competitors

Thermo Fisher Scientific (TMO)Thermo Fisher Scientific, a broad life-sciences tools, diagnostics, and laboratory services company.
Danaher (DHR)Danaher, a diversified life-sciences and diagnostics group with laboratory instrument businesses.
Waters (WAT)Waters, a specialist in analytical technologies, including chromatography and mass spectrometry.

Competitive Advantages

  • Installed Base: Instruments placed in laboratories can support follow-on demand for service, maintenance, and consumables.
  • Customer Switching Costs: In validated or regulated workflows, a supplier change may require testing, staff training, and documentation, which can favor established platforms.
  • Technical Breadth: A portfolio spanning instruments, software, and services allows Agilent to address multiple laboratory needs, though rivals also offer broad and specialized solutions.

Earnings Track Record

Last 4 Quarters: 1 documented beat / 0 documented misses; three quarter-level results were not provided

Recent Earnings History

2026-08-26 report$1.62 vs $1.49 estBEAT
Prior quarterActual and estimate not providedUNAVAILABLE
Prior quarterActual and estimate not providedUNAVAILABLE
Prior quarterActual and estimate not providedUNAVAILABLE

Guidance Trend

No management guidance revisions or full quarterly earnings history were supplied, so a trend in estimate beats or guidance changes cannot be verified. The next reported EPS estimate is $1.73 for November 23. You’ll want to compare both the reported result and management’s commentary on demand, margins, and the outlook with that estimate rather than relying on the previous beat alone.

Analyst Sentiment

Consensus Rating: Strong Buy, according to the supplied 22-analyst survey

Strong Buy: 3 Buy: 12 Hold: 7 Sell: 0

Price Targets

  • Low: $150
  • Mean: $174.29 (+0.2% upside)
  • High: $195

Recent Analyst Actions

No individual recent upgrades or downgrades were included. While 15 of 22 analysts in the supplied breakdown use a Strong Buy or Buy label, seven rate the shares Hold. A separate market-data snapshot records 20 opinions and a $182.05 mean target, so target coverage and source timing differ. These are third-party views, not a guarantee of future performance.

Recent News & Catalysts

Key Developments

  • Evercore Healthcare Conference: Agilent announced November 12 that management would participate in the 9th Annual Evercore Healthcare Conference. Investor attention may focus on any commentary about demand and the business outlook.
  • SureSelect Cancer Research Pan Heme: The November 10 announcement expands Agilent’s cancer research next-generation sequencing portfolio. Adoption and revenue contribution are not quantified in the available release summary.
  • Recent EPS Beat: The August 26 report showed EPS of $1.62 against a $1.49 estimate. The result is a positive data point, while the next report will offer a more current read on operating performance.

Upcoming Catalysts

Next Earnings: November 23, 2026, expected EPS $1.73 | Key Events: Quarterly results and guidance, management commentary at the Evercore conference, and early market response to the new cancer research product

Technical Outlook

Current Price: $173.96 vs 52-Week High: $182.99 (4.9% below the high)

Trend Analysis

Friday’s close was near the upper end of the stated 52-week range of $108.35 to $182.99, consistent with a strong recovery from the yearly low. The supplied two-year Yahoo Finance snapshot reports a 35.68% total return, but no moving averages, volume trend, or relative-strength readings were provided. That limits the ability to confirm trend strength using standard technical indicators. Markets are closed for the weekend, with the next US trading session scheduled for Monday, November 16.

Key Levels

  • Resistance: Around $175 as a near-term round-number reference, then the 52-week high near $182.99
  • Support: Friday’s intraday low near $170.79, then the approximate $165 to $160 area as a lower reference zone; these are not confirmed technical levels

Bull vs Bear Case

Bull Case

  • Recent Execution: The latest supplied quarterly EPS exceeded its estimate by $0.13, and supplemental data indicates revenue and earnings growth.
  • Portfolio Expansion: New cancer research sequencing products add to Agilent’s life-sciences offerings and could broaden customer applications if adopted.
  • Analyst Support: Fifteen of 22 analysts in the supplied survey rate the shares Strong Buy or Buy, with the high target at $195.

Bull Target: $195, the supplied high analyst target, about 12.1% above Friday’s close

Bear Case

  • Limited Mean-Target Gap: The supplied mean target of $174.29 is almost equal to the $173.96 close.
  • Valuation Sensitivity: A 34.18 trailing P/E and 6.66 price-to-book ratio leave the shares exposed if growth or margins disappoint.
  • Uncertain Product Impact: The new portfolio announcement provides no quantified sales outlook, and laboratory spending can vary with customer budgets.

Bear Target: $150, the supplied low analyst target, about 13.8% below Friday’s close

Risks to Consider

  • Valuation Risk: Premium earnings and book multiples may amplify share-price sensitivity to weaker guidance, slower growth, or higher discount rates.
  • Competitive Risk: Large diversified rivals and specialist instrument providers compete on performance, price, service, and customer relationships.
  • Macro Risk: Research and laboratory budgets can be affected by economic uncertainty, funding conditions, and changes in pharmaceutical or biotech spending.
  • Execution Risk: Product launches require customer adoption, reliable delivery, and continued product quality. The available announcement does not quantify expected contribution from the new sequencing solution.
  • Data and Timing Risk: Financial snapshots report slightly different EPS and ROE values, while analyst targets differ between data sources. Investors comparing figures should check reporting dates and definitions.

Bottom Line

Investment Verdict: NEUTRAL

Agilent has established laboratory franchises, a reported quarterly EPS beat, and a broadly positive analyst survey. At Friday’s $173.96 close, though, the supplied mean target points to little implied price appreciation, while the premium valuation and November 23 earnings event leave the near-term balance dependent on results and guidance. This report is informational analysis, not investment advice.

Action Items for Investors

  • Long-term investors: Monitor revenue growth, recurring service and consumables demand, margins, and whether new product introductions translate into measurable sales. These are analytical checkpoints, not a personalized course of action.
  • Short-term traders: Track the November 23 report and the stated $170.79 intraday low and $182.99 52-week high as reference points, while recognizing that price levels can change and are not forecasts.
  • Risk management: Consider the effect of valuation, earnings volatility, and differing analyst estimates when assessing portfolio exposure; align any decisions with personal circumstances and independent advice where appropriate.

What to Watch This Week

  • Any new commentary from management at the Evercore Healthcare Conference.
  • Trading after the weekend, beginning Monday, November 16, and how the shares behave relative to Friday’s range.
  • Preparation for the November 23 earnings report, particularly the $1.73 EPS estimate and any available updates to company guidance.

Share this report

Share this article

Spread the word on social media

Think A will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.